24EL-402 On-Demand eCast: Improving HPC Inventory Management - Considerations Regarding Consent and Discard of Cryopreserved HPC Products

Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)

Live Program Date: Wednesday, January 17, 2024
Program Number: 24EL-402

Educational Track: Quality Education
Topics: Biotherapies
Intended Audience: Directors, Laboratory Staff, Managers/Supervisors, Medical Directors
Teaching Level: Intermediate

Faculty
(titles and affiliations at the time of the live program)
Director/ Speaker: Melissa Marlowe, CHS, MBA, Vice President, Clinical Services Administration, Vitalant, Phoenix, AZ
Moderator: Christina Celluzzi, PhD, MS, CABP(H), Director, Biotherapies, AABB, Bethesda, MD

Program Description
This program will address challenges that labs face related to the long-term storage of cryopreserved products and inventory management. Examples of consent documents will be discussed and how expectations for length of storage has changed over the past 10-15 years. Case studies will be used to demonstrate challenging situations that the lab/storage program may face and options to consider while evaluating a product for discard.

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Identify key elements of a strong consent document.
  • List common challenges faced by Cellular Therapy storage programs when evaluating products for discard.
  • Describe how changing clinical and industry expectations impact storage terms and approval for discard.

How to Claim Continuing Education Credit

  • Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.
  • Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.

Moderator

Speaker Image for Christina Celluzzi
Christina Celluzzi, PhD,MS, CABP(H)
Director, Biotherapies, AABB

Director & Speaker

Speaker Image for Melissa Marlowe
Melissa Marlowe, CHS, MBA
Vice President, Vitalant

Related Products

Thumbnail for AM24-MN-26-O: Overview of Cell-Based Biologics Manufacturing as a Contracted Service (Enduring)
AM24-MN-26-O: Overview of Cell-Based Biologics Manufacturing as a Contracted Service (Enduring)
Decentralized manufacturing has become a prominent focus in the Advanced Therapies space as the number of therapies in development increases and patient volumes surge with earlier line treatment objectives…
Thumbnail for AM24-TU-11-O: Managing Risk, Maximizing Safety: The Essentials of Proactive Risk Assessment (Enduring)
AM24-TU-11-O: Managing Risk, Maximizing Safety: The Essentials of Proactive Risk Assessment (Enduring)
This session equips blood bank, transfusion medicine, and biotherapies professionals with practical tools for robust risk assessment. Risk identification methods and customizing risk registers for specific practice areas will be covered…
Thumbnail for AM24-SN-09-O: Lesson's Learned Onboarding Cell and Gene Therapy Vendors and Clients in the 21st Century (Enduring)
AM24-SN-09-O: Lesson's Learned Onboarding Cell and Gene Therapy Vendors and Clients in the 21st Century (Enduring)
37 cell and gene therapy (CGT) products licensed in the US with a steady pipeline of anticipated approvals moving forward. Each one of these has a unique contracting and onboarding process…
Thumbnail for AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection?  Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate (Enduring)
AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection? Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate (Enduring)
This informative session will give an overview of inspections conducted by FDA’s Office of Inspections and Investigations (OII), Office of Biologics Inspectorate (OBI), including OBI’s role in regulatory inspections and current regulatory oversight…